Yes. Numinus currently offers ketamine-assisted psychotherapy. Additionally, we are undertaking clinical trials with MDMA- and psilocybin-assisted psychotherapy to help further the body of research supporting their approval as treatments for a variety of conditions. We plan to offer these treatments as the regulatory landscape in North America changes, and our Clinical Advisory Board continues to support those policy changes starting here in Canada. Read our recommendation letter to Health Canada for more.
July 9, 2021